Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic steatohepatitis (NASH)Â San […]